The Food and Drug Administration and the Centers for Disease Control and Prevention are recommending a single dose of Johnson & Johnson to “suspend”vaccine to consider clotting cases.
The agencies said in a statement on Tuesday the CDC will convene a meeting of the Advisory Committee on Immunization Practices on Wednesday to review six cases of “a rare and serious type of blood clot. “in people who have had the vaccine. FDA will then review that analysis as it is also investigating the cases.
Dr. Anne Schuchat, CDC’s Senior Vice President and Dr. Peter Marks, Director of FDA Biology Center, said: “Until that process is complete, we recommend suspending use of this vaccine. . Reviews and Research, “said in the statement.
As of Monday, more than 6.8 million single-dose doses of vaccine have been used nationwide.
Officials in multiple states said as early as Tuesday they were arguing to determine how the decision affects current vaccine supply and distribution plans.
The cases the FDA and CDC are investigating are occurring in women and involve blood clots known as cerebral sinus thrombosis, which are seen along with low blood platelet counts, according to their claims. Symptoms are seen 6 to 13 days after vaccination in women, who are between the ages of 18 and 48.
“Treatment of this particular type of blood clot differs from the usual treatment that may be used. Usually, an anticoagulant drug called heparin is used to treat the blood clot. , the use of heparin can be dangerous and alternative treatments need to be given, “they said.
Agencies say “adverse events” appear extremely rare, but pauses are important so that healthcare providers can be aware of reactions and recognize and manage Correct cases, with only necessary treatment.
Ed O’Keefe contributed to the report.